BioPharma

Speeding up biomanufacturing using automated Process Analytical Technology (PAT) systems A2P2 and Micro Sequential Injection (SI), two cutting-edge process analysers, have been cited as autonomous PAT platform that enables quick testing and release of biopharmaceutical products. An insight has showcased two...

Gene and cell therapies have the potential to revolutionize healthcare by reprogramming the immune system to treat diseases that are difficult to address with traditional medicine. These therapies involve introducing, replacing, or deactivating genes in cells, either inside or...

New recommendations from Imperial College London aim to boost competitiveness in the UK's biopharma and Medtech sectors. It assesses the value-added per capita in these sectors and provides insights into their needs, challenges, and opportunities. Technological solutions and policy...

The global cell and gene therapy Contract Development and Manufacturing Organization (CDMO) services market, which was valued at USD 5,193.7 million in 2022, is expected to grow at a CAGR of 17.5% during the forecast period from 2023 to...

Standfirst: The healthcare industry, particularly the life-science and biopharma sectors, across ASEAN is seeing a shift away from a reliance on overseas expertise and imported products and technology towards a preference for homegrown solutions. The growth in South East Asia’s...

CDMOs (contract development and manufacturing organizations) are facing challenges due to the increasing number of companies preparing to scale up their cell and gene therapy manufacturing for Phase III trials and commercialization. While physical capacity has been blamed, the...

uBriGene, a cell & gene therapy contract development and manufacturing organization (CDMO), is expanding into the US market with the acquisition of a state-of-the-art GMP manufacturing facility from NASDAQ-listed company Mustang Bio, Inc. The cell & gene therapy (CGT) CDMO...